Search

everythinglearnresearchcommunity

for

Search:↓

Chrysin makes docetaxel more effective and reduces its side effects in lung cancer treatment.

Chemotherapy significantly lowers Inhibin A levels in breast cancer patients.

Some breast cancer patients treated with high-dose docetaxel may experience permanent hair loss.

New drugs and therapies targeting specific pathways show promise in treating advanced prostate cancer.

Taxane chemotherapy can cause skin, hair, and nail side effects, which are often under-reported and can affect patient quality of life.

Scalp cooling significantly reduces hair loss in chemotherapy patients.

Docetaxel and oxaliplatin are effective and have manageable side effects for recurrent platinum-sensitive ovarian cancer.

Docetaxel is safe and works well for older people with cancer, with manageable side effects.

The new chemotherapy combination for advanced lung cancer showed a 35.7% response rate but caused significant side effects.

Pemetrexed is as effective as docetaxel but has fewer side effects for treating nonsmall-cell lung cancer after EGFR-TKI therapy failure.

Chemotherapy with docetaxel and cisplatin can cause severe low potassium, requiring careful monitoring and treatment.

Some breast cancer chemotherapy can cause permanent hair loss.

In 2002, various skin reactions were reported due to different drugs, including allergies, hair loss, skin lesions, and other skin conditions.

The FDA approved a new breast cancer treatment, found flu shots may reduce heart risks, questioned the safety of fast-tracked drug approvals, showed statins don't help with certain pneumonia, and approved a new dementia imaging agent.

p14ARF and p16Ink4a cause hair follicle stem cell aging and dysfunction.

Cooling the scalp may prevent hair loss from chemotherapy, hair often grows back after treatment, and nail issues usually improve after stopping the drug.

5-Alpha reductase inhibitors may prevent prostate cancer but are not widely used due to concerns about trial relevance and potential risks, and more research is needed to confirm long-term benefits.

Triple Hormonal Blockade (ADT3) can effectively manage prostate cancer but requires careful monitoring for heart risks.

Patients with advanced breast cancer and high hormone receptor levels who had surgery for ovarian/pelvic metastases lived longer, especially if they had high estrogen receptor levels.

The Li-Pa/Ca and Do/Ca chemotherapy regimens for serous ovarian cancer showed better short-term and long-term results than the Pa/Ca regimen.

The combination therapy is effective and well-tolerated for treating esophageal cancer.

Many adult women experience unexplained excessive hair shedding, often starting before age 40.

Chemotherapy can cause permanent, non-reversible hair loss similar to pattern baldness.

Human dental pulp stem cell-conditioned medium, especially from hypoxic conditions, may help treat chemotherapy-induced hair loss and does not increase cancer risk.

Scientists made the first metal-based compounds from a nonsteroidal antiandrogen drug, which showed potential in fighting both hormone-dependent and independent prostate cancer cells.

Gefitinib can cause skin problems, diarrhea, and nausea, but rarely causes severe lung disease or hair loss.

The document concludes that systemic therapy is becoming more important in treating head and neck cancer, with new treatments showing promise.

The new chemotherapy combination of WP 631 and Epothilone B shows enhanced effectiveness against ovarian cancer but requires more research on its safety.

The new finasteride delivery system using chitosan-based nanoniosomes shows promise for prostate cancer prevention.

KRTAP2-3 could help predict cancer recurrence by identifying specific cancer cells.